지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 영남대학교 의과대학 Journal of Yeungnam Medical Science Yeungnam University Journal of Medicine 제36권 제2호
- 발행연도
- 2019.1
- 수록면
- 67 - 77 (11page)
이용수
초록· 키워드
오류제보하기
The paradigm of chronic liver diseases has been shifting. Although hepatitis B and C viral infections are still the main causes of liver cirrhosis and hepatocellular carcinoma (HCC), the introduction of effective antiviral drugs may control or cure them in the near future. In contrast, the burden of nonalcoholic fatty liver disease (NAFLD) has been increasing for decades, and 25 to 30% of the general population in Korea is estimated to have NAFLD. Over 10% of NAFLD patients may have nonalcoholic steatohepatitis (NASH), a severe form of NAFLD. NASH can progress to cirrhosis and HCC. NASH is currently the second leading cause to be placed on the liver transplantation list in the United States. NAFLD is associated with obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. The pathophysiology is complex and associated with lipotoxicity, inflammatory cytokines, apoptosis, and insulin resistance. The only proven effective treatment is weight reduction by diet and exercise. However, this may not be effective for advanced fibrosis or cirrhosis. Therefore, effective drugs are urgently needed for treating these conditions. Unfortunately, no drugs have been approved for the treatment of NASH. Many pharmaceutical companies are trying to develop new drugs for the treatment of NASH. Some of them are in phase 2 or 3 clinical trials. Here, pharmacologic therapies in clinical trials, as well as the basic principles of drug therapy, will be reviewed, focusing on pathophysiology.
목차
등록된 정보가 없습니다.
참고문헌 (49)
참고문헌 신청
Oh H / 2016 / Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment / Clin Mol Hepatol 22:327~335
Alkhouri N / 2009 / Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal / Expert Rev Gastroenterol Hepatol 3:445~451
Malhi H / 2008 / Cellular and molecular mechanisms of liver injury / Gastroenterology 134:1641~1654
Yang L / 2014 / Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice / Hepatology 59:483~495
Okazaki I / 2018 / Non-alcoholic steatohepatitis / Koonja Publishing Inc
Alkhouri N / 2009 / Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal / Expert Rev Gastroenterol Hepatol 3:445~451
Malhi H / 2008 / Cellular and molecular mechanisms of liver injury / Gastroenterology 134:1641~1654
Yang L / 2014 / Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice / Hepatology 59:483~495
Okazaki I / 2018 / Non-alcoholic steatohepatitis / Koonja Publishing Inc
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
영남의대학술지
2019 .01
-
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Clinical and Molecular Hepatology
2023 .02
-
Recent research trends and updates on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2019 .01
-
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Endocrinology and Metabolism
2022 .02
-
비알코올성 지방간 질환의 진단적 평가
대한내과학회지
2020 .10
-
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2020 .01
-
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Clinical and Molecular Hepatology
2023 .02
-
The Immune Landscape in Nonalcoholic Steatohepatitis
Immune Network
2016 .06
-
Liver Transplantation for HCC in NASH/NAFLD Patients: Outcomes and Complications
대한외과학회 학술대회 초록집
2021 .11
-
Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease
Gut and Liver
2023 .01
-
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Clinical and Molecular Hepatology
2023 .02
-
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Diabetes and Metabolism Journal
2019 .01
-
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
Diabetes and Metabolism Journal
2020 .01
-
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Clinical and Molecular Hepatology
2023 .02
-
Risk factors in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients
전남의대학술지
2024 .01
-
Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease
Journal of Obesity & Metabolic Syndrome
2022 .03
-
Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights
Clinical and Molecular Hepatology
2020 .01
-
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
Clinical and Molecular Hepatology
2023 .02
-
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Clinical and Molecular Hepatology
2022 .10
이 논문의 저자 정보
최근 본 자료
댓글(0)
0